A multicenter, randomized, double-blind, chronic-dosing, parallel-group, placebo-controlled phase 3 study to evaluate the efficacy and safety of bendralizumab 100mg in patietns with moderate to very severe chronic obstructive pulmonary disease (COPD) wiht a history of frequent COPD exacerbations and elevated peripheral blood eosinophils. (RESOLUTE) (NCT04053634)
RESOLUTE
This trial is No longer recruiting
Registration number NCT04053634
Program & service
This trial is being run with the Heart & Lung service, and as part of the Respiratory program.
Trial phase
Phase 3
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Associate Professor Eli Dabscheck
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR